Key facts
- Theraheart’s last known valuation is $35.4M (Sep 2025).
- It has raised $23.0M across 1 recorded rounds; the latest was Early Stage VC ($11.6M) in Sep 2025.
- Notable investors include Qiming Venture Partners.
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Theraheart
Funding rounds
1 roundsAbout Theraheart
Developer of implantable cardiac medical devices designed to assist patients with advanced heart failure. The company offers minimally invasive support systems with wireless energy transfer and remote monitoring, enabling hospitals and cardiac care providers to deliver long-term circulatory assistance and improve outcomes for patients with severe heart conditions.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2023
- Employees
- 5
- Website
- theraheart.com/
- Ownership
- Privately Held (backing)
Theraheart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Theraheart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Theraheart in its N-PORT filings yet. We sweep new filings monthly.